,56 This relationship between GM-CSF and CCL17 can be used to measure the efficacy of other anti-GM-CSF therapies since decreased CCL17 serum levels in RA patients correlate with increased therapeutic efficacy.5 This evidence concerns the gene CCL17 and rheumatoid arthritis.